natgillin/translations-raw huggingface dataset:
Like all medicines, ZOSTAVAX can cause side effects, although not everybody gets them.
Kot vsa cepiva ima lahko tudi cepivo ZOSTAVAX neželene učinke, ki pa se ne pojavijo pri vseh osebah.
In studies, the most commonly reported side effects (occurring in at least 1 in 10 individuals) were at the injection site.
39 V študijah so najpogosteje poročali o neželenih učinkih na mestu injiciranja cepiva (pojavili so se vsaj pri 1 od 10 oseb).
These side effects included redness, pain, swelling, itching, warmth, and bruising at the injection site.
Ti neželeni učinki vključujejo rdečino, bolečino, oteklino, srbenje, toploto in modrico na mestu injiciranja.
Headache was also commonly reported (occurring in at least 1 of 100 and less than 1 of 10 individuals).
Pogosto so poročali tudi o glavobolu (pojavil se je pri več kot 1 od 100, vendar manj kot 1 od 10 oseb).
The following additional side effects have been reported in general use with ZOSTAVAX: fever; rash; allergic reactions, which may be serious and may include difficulty in breathing or swallowing.
V obdobju trženja zdravila Zostavax so poročali o naslednjih neželenih učinkih: zvišana telesna temperatura, izpuščaj, alergijska reakcija, ki je lahko huda in vključuje težave pri dihanju in požiranju.
If you have an allergic reaction, call your doctor right away.
Če imate alergijsko reakcijo, nemudoma obvestite svojega zdravnika.
Your doctor or pharmacist has a more complete list of side effects for ZOSTAVAX.
Vaš zdravnik in farmacevt imata popolnejši seznam neželenih učinkov cepiva ZOSTAVAX.
If the condition persists or worsens, seek medical attention.
Če se stanje ne izboljša ali se poslabšuje, poiščite zdravniško pomoč.
HOW TO STORE ZOSTAVAX
SHRANJEVANJE CEPIVA ZOSTAVAX
Do not use ZOSTAVAX after the expiry date which is stated on the outer carton after EXP.
Cepiva ZOSTAVAX ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake EXP.
What ZOSTAVAX contains After reconstitution, 1 dose (0.65 ml) contains:
Kaj vsebuje cepivo ZOSTAVAX Po rekonstituciji 1 odmerek (0, 65 ml) vsebuje:
Varicella-zoster virus1, Oka/ Merck strain, (live, attenuated) not less than 19400 PFU (plaque-forming units).
Virus varicella- zoster1, sev Oka/ Merck, (živ, oslabljen), ne manj kot 19. 400 enot, ki tvorijo plak (PFU – plaque forming units).
1 Produced in human diploid (MRC-5) cells
1 Pridobljen na humanih diploidnih (MRC- 5) celicah.
Powder Sucrose, hydrolysed gelatin, sodium chloride, potassium dihydrogen phosphate, potassium chloride, monosodium L-glutamate, anhydrous disodium phosphate, sodium hydroxide (to adjust pH), and urea.
Prašek Saharoza, hidrolizirana želatina, natrijev klorid, kalijev dihidrogenfosfat, kalijev klorid, natrijev L - glutamat, brezvodni natrijev hidrogenfosfat, natrijev hidroksid (za uravnavo pH) in sečnina.
What ZOSTAVAX looks like and contents of the pack
Izgled cepiva ZOSTAVAX in vsebina pakiranja Cepivo v obliki praška za suspenzijo za injiciranje se nahaja v enoodmerni viali.
41 The vaccine is a powder for suspension for injection contained in a single-dose vial, which should be reconstituted with the solvent provided with the vial of powder.
Pred uporabo ga je treba pripraviti z vehiklom, ki se nahaja v priloženi viali.
Before mixing with the solvent, the powder is a white to off- white compact crystalline plug.
Pred dodajanjem vehikla je prašek bel do sivo- bel v grudo stisnjen kristalni prašek.
Marketing Authorisation Holder and Manufacturer
40 Imetnik dovoljenja za promet s cepivom in izdelovalec
Marketing Authorisation Holder:
Imetnik dovoljenja za promet s cepivom:
This leaflet was last approved in:
41 Navodilo je bilo odobreno:
42 The following information is intended for medical or healthcare professionals only:
Naslednje informacije so namenjene samo zdravstvenemu osebju:
When completely reconstituted, the vaccine is a semi-hazy to translucent, off-white to pale yellow liquid.
Po rekonstituciji je cepivo pol motna do prosojna, sivo- bela do bledo rumena tekočina.
Withdraw the entire volume of solvent into a syringe.
Celoten volumen vehikla izvlecite v injekcijsko brizgo.
Gently agitate to dissolve completely.
Nežno tresite, da se prašek popolnoma raztopi.
Withdraw the entire content of the reconstituted vaccine vial into a syringe for injection.
Celotno vsebino rekonstituiranega cepiva izvlecite iz viale v injekcijsko brizgo za injiciranje cepiva.
It is recommended that the vaccine be administered immediately after reconstitution to minimize loss of potency.
Priporočamo, da cepivo aplicirate takoj po rekonstituciji, da se zmanjša možnost izgube učinkovitosti.
Do not use the reconstituted vaccine if you notice any particulate matter or if the appearance of the solvent or powder or of the reconstituted vaccine differs from that described above.
Če opazite kakršnekoli tuje delce ali če je izgled vehikla, praška ali pripravljenega cepiva drugačen od zgoraj opisanega, rekonstituiranega cepiva ne uporabite.
HOW TO USE ZOSTAVAX
KAKO SE UPORABLJA CEPIVO ZOSTAVAX.
ZOSTAVAX Powder and solvent for suspension for injection in a pre-filled syringe zoster vaccine (live)
ZOSTAVAX Prašek in vehikel za suspenzijo za injiciranje v napolnjeni brizgi cepivo proti herpesu zostru (živo)
44 • if you have been told by your doctor that you have a weakened immune system as a result of a disease, medicines, or other treatment • if you have active untreated tuberculosis • if you are pregnant (see Pregnancy and breast-feeding)
Dodatne informacije - Kaj vsebuje cepivo ZOSTAVAX); • če imate krvno bolezen ali katerokoli vrsto raka, ki je oslabil vaš imunski sistem; • če vam je zdravnik povedal, da imate zaradi bolezni, zdravil ali drugih oblik zdravljenja oslabljen imunski sistem; • če imate aktivno, nezdravljeno tuberkulozo; • če ste noseči (glejte Nosečnost in dojenje).
Take special care with ZOSTAVAX
43 Bodite posebno pozorni pri cepljenju s cepivom ZOSTAVAX
Women of child-bearing age should take the necessary precautions to avoid pregnancy for 3 months following vaccination.
Ženske v rodni dobi morajo 3 mesece po cepljenju poskrbeti za ustrezno zaščito pred zanositvijo.
In studies, the most commonly reported side effects (occurring in at least 1 in 10 individuals) were at the injection site.
V študijah so najpogosteje poročali o neželenih učinkih na mestu injiciranja cepiva (pojavili so se vsaj pri 1 od 10 oseb).
Varicella-zoster virus1, Oka/ Merck strain, (live, attenuated) not less than 19400 PFU (plaque-forming units).
Virus varicella- zoster1, sev Oka/ Merck, (živ, oslabljen), ne manj kot 19. 400 enot, ki tvorijo plak (PFU – plaque- forming units).
What ZOSTAVAX looks like and contents of the pack
Pred uporabo ga je treba pripraviti z vehiklom, ki se nahaja v priloženi viali.
46 The vaccine is a powder for suspension for injection contained in a single-dose vial, which should be reconstituted with the solvent provided with the vial of powder.
Pred dodajanjem vehikla je prašek bel do sivo- bel v grudo stisnjen kristalni prašek.
Before mixing with the solvent, the powder is a white to off- white compact crystalline plug.
Eno pakiranje cepiva ZOSTAVAX vsebuje vialo in napolnjeno injekcijsko brizgo s pritrjeno iglo ali brez nje.
One pack of ZOSTAVAX contains a vial and a prefilled syringe with or without attached needles.
V škatli z napolnjeno injekcijsko brizgo brez pritrjene igle sta lahko posebej priloženi ena ali 2 igli.
One or 2 separate needles may be available in the secondary packaging of the presentation containing the pre- filled syringe without the attached needle ZOSTAVAX is available in packs of 1, 10 or 20 with or without needles.
Cepivo ZOSTAVAX je na voljo v pakiranjih po 1, 10 ali 20 z ali brez igle.
This leaflet was last approved in:
46 Navodilo je bilo odobreno:
47 The following information is intended for medical or healthcare professionals only:
Naslednje informacije so namenjene samo zdravstvenemu osebju:
The needle should be pushed into the extremity of the syringe and rotated a quarter of a turn (90°) to secure the connection.
Iglo morate potisniti na konico brizge in jo obrniti za četrt obrata (90 º), da je pravilno nameščena.
Zypadhera is a powder and solvent that are made up into a prolonged-release suspension for injection.
Zdravilo Zypadhera sestavljata prašek in vehikel, iz katerih pripravimo suspenzijo za injiciranje s podaljšanim sproščanjem.
It contains the active substance olanzapine. ‘ Prolonged release ’ means that the active substance is released slowly over a few weeks after being injected.
Izraz podaljšano sproščanje pomeni, da se zdravilna učinkovina po vbrizganju sprošča nekaj tednov.
Zypadhera is used to maintain the improvement in symptoms in patients with schizophrenia who have already been stabilised on an initial course of olanzapine taken by mouth.
Zdravilo Zypadhera se uporablja za vzdrževanje izboljšanja simptomov pri bolnikih s shizofrenijo, ki so že dosegli stabilno stanje v začetnemu zdravljenju z olanzapinom peroralno (skozi usta).
Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).
Shizofrenija je duševna bolezen, ki ima vrsto simptomov, vključno z neorganiziranim mišljenjem in govorom, halucinacijami (bolnik vidi ali sliši stvari, ki jih v resnici ni), sumničavostjo in blodnjami (zmotna prepričanja).
Zypadhera is given by deep injection into the buttock muscle by a doctor or nurse who has been trained in giving this type of injection.
Zdravilo Zypadhera da z globokim vbrizganjem v zadnjično mišico zdravnik ali sestra, ki sta usposobljena za tako vbrizganje.
In rare cases, patients receiving Zypadhera may experience symptoms of olanzapine overdose after injection if the medicine is accidentally injected into a vein.
V redkih primerih se lahko pri bolnikih, ki prejemajo zdravilo Zypadhera, pojavijo simptomi prekomernega odmerka olanzapina po injekciji, če zdravilo po nesreči vbrizgate v veno.
Because patients should be monitored by qualified staff for these symptoms for at least three hours after injection, they should receive Zypadhera at a centre with the appropriate facilities to deal with a potential overdose.
Ker mora za ugotavljanje pojava teh simptomov bolnike vsaj tri ure po vbrizganju nadzorovati usposobljeno osebje, morajo bolniki zdravilo Zypadhera prejeti v centru, ki je primerno opremljen za ukrepanje ob morebitnem prekomernem odmerku.
Zypadhera is given at doses of 150, 210 or 300 mg every two weeks, or 300 or 405 mg every four weeks.
Zdravilo Zypadhera se daje v odmerku 150 ali 210 mg vsake dva tedna oziroma v odmerku 300 ali 405 mg vsake štiri tedne.
However, patients aged between 65 and 75 years or patients with kidney or liver problems may use Zypadhera if an effective and well- tolerated dose of oral olanzapine has been found.
Vendar pa lahko bolniki, stari od 65 do 75 let, ali bolniki z ledvičnimi oziroma jetrnimi težavami zdravilo Zypadhera uporabljajo, če so ugotovili odmerek peroralnega olanzapina, ki je učinkovit in ga bolniki dobro prenašajo.
It is known as an ‘ atypical’ antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s.
Znano je kot netipično antipsihotično zdravilo, ker se razlikuje od starejših antipsihotičnih zdravil, ki so na voljo od petdesetih let prejšnjega stoletja.
This disrupts signals transmitted between brain cells by ‘ neurotransmitters’, chemicals that allow nerve cells to communicate with each other.
S tem se prekinejo signali, ki se prenašajo med možganskimi celicami z živčnimi prenašalci, kemičnimi spojinami, ki živčnim celicam omogočajo medsebojno sporazumevanje.
It is thought that olanzapine’ s beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytrypamine (also called serotonin) and dopamine.
Predvideva se, da olanzapin koristno učinkuje z blokiranjem receptorjev za živčna prenašalca 5 - hidroksitripamin (imenovan tudi serotonin) in dopamin.
Since these neurotransmitters are involved in schizophrenia, olanzapine helps to normalise the activity of the brain, reducing the symptoms of the disease.
Ker ti živčni prenašalci sodelujejo pri shizofreniji, olanzapin pomaga normalizirati aktivnost možganov in oslabi simptome bolezni.
It is available as tablets, orodispersible tablets (tablets that dissolve in the mouth) and rapidly acting injections in Zyprexa, Zyprexa Velotab and other medicines.
Na voljo je v obliki tablet, orodisperzibilnih tablet (tablet, ki se raztopijo v ustih) in hitro delujočih injekcijskih brizg ter kot zdravilo Zyprexa, Zyprexa Velotab ter druga zdravila.
The olanzapine in Zypadhera is presented as a ‘ pamoate’ salt, which makes the olanzapine less soluble.
Olanzapin v zdravilu Zypadhera je v obliki soli pamoata, zaradi česar je manj topen.
Because olanzapine has already been authorised in the EU as Zyprexa, the company used some of the data from Zyprexa to support the use of Zypadhera.
Ker so olanzapin že odobrili v EU kot zdravilo Zyprexa, je družba uporabila nekatere podatke o zdravilu Zyprexa v podporo uporabi zdravila Zypadhera.
Zypadhera has been studied in two main studies involving adults with schizophrenia.
Zdravilo Zypadhera so raziskali v dveh glavnih študijah, ki sta vključevali odrasle s shizofrenijo.
The first looked at the initial treatment of schizophrenia and the second looked at the maintenance of response to olanzapine treatment: • the study of initial treatment compared the effects of three doses of Zypadhera with those of placebo (dummy injections) in 404 patients.
V prvi študiji so opazovali začetno zdravljenje shizofrenije, v drugi pa so opazovali vzdrževanje odziva na zdravljenje z olanzapinom: • v študiji začetnega zdravljenja so primerjali učinke treh odmerkov zdravila Zypadhera z učinki placeba (injekcijami zdravila brez zdravilne učinkovine) pri 404 bolnikih.
The main measure of effectiveness was the change in symptoms measured on a standard scale for schizophrenia after eight weeks; • the study of maintenance treatment compared the effects of four doses of Zypadhera with those of olanzapine taken by mouth in 1,065 patients.
Glavno merilo učinkovitosti so bile spremembe v simptomih, ki so jih merili s standardno lestvico shizofrenije po osmih tednih; • v študiji vzdrževalnega zdravljenja so primerjali učinke štirih odmerkov zdravila Zypadhera z učinki peroralno zaužitega olanzapina pri 1 065 bolnikih.
Three of the doses of Zypadhera were ‘ high’ (300 mg and 150 mg every two weeks, and 405 mg every four weeks) and one was ‘ low’ (45 mg every four weeks).
(45 mg vsake štiri tedne).
The main measures of effectiveness were the time taken for symptoms to get worse and the number of patients whose symptoms got worse over 24 weeks.
Glavna merila učinkovitosti sta bila čas, potreben za poslabšanje simptomov, in število bolnikov, katerih simptomi so se poslabšali v 24 tednih.
The effectiveness of Zypadhera was greater than placebo from the second week of treatment onwards.
Učinkovitost zdravila Zypadhera je bila večja od placeba od drugega tedna zdravljenja dalje.
10% of the patients receiving Zypadhera every two weeks had a worsening of symptoms, compared with 7% of those taking olanzapine by mouth.
V študiji, s katero so opazovali vzdrževanje odziva na zdravljenje z olanzapinom, je bilo zdravilo Zypadhera enako učinkovito kot olanzapin, ki so ga bolniki jemali peroralno: pri 10% bolnikov, ki so prejemali zdravilo Zypadhera vsake dva tedna, so se simptomi poslabšali, v primerjavi s 7% tistih, ki so olanzapin jemali peroralno.
The ‘ high’ doses of Zypadhera were more effective at preventing a worsening of symptoms than the ‘ low’ dose.
Veliki odmerki zdravila Zypadhera so bili bolj učinkoviti pri preprečevanju poslabšanja simptomov kot nizki odmerki.
The most common side effects with Zypadhera (seen in more than 1 patient in 10) are weight gain, somnolence (sleepiness) and raised levels of prolactin (a hormone).
Najpogostejši neželeni učinki zdravila Zypadhera (opaženi pri več kot 1 bolniku izmed 10) so povečana telesna masa, zaspanost in zvišana koncentracija prolaktina (hormon).
For the full list of all side effects reported with Zypadhera, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zypadhera, glejte navodilo za uporabo.
Zypadhera should not be used in patients who may be hypersensitive (allergic) to olanzapine or any of the other ingredients.
Zdravila Zypadhera ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) olanzapin ali katero koli drugo sestavino zdravila.
It must not be used in patients at risk of narrow-angle glaucoma (raised pressure inside the eye).
Zdravila ne smejo uporabljati bolniki, pri katerih obstaja tveganje glavkoma zaprtega zakotja (povečan tlak v očesu).
The Committee for Medicinal Products for Human Use (CHMP) noted that Zypadhera is effective both in the initial treatment of schizophrenia and in maintaining a response to treatment in schizophrenia.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je zdravilo Zypadhera učinkovito zdravilo za začetno zdravljenje shizofrenije in pri vzdrževanju odziva na zdravljenje 2/ 3 shizofrenije.
However, it noted that prolonged-release injections are not suitable for use as initial treatment, because the medicine takes at least a week to reduce symptoms and patients may need rapid control of symptoms.
Vendar pa je odbor ugotovil, da injekcije s podaljšanim izločanjem niso primerne kot začetno zdravljenje, ker zdravilo potrebuje vsaj en teden, da ublaži simptome, bolniki pa bi morda potrebovali hiter nadzor simptomov.
In addition, it is not possible to stop treatment after giving a prolonged-release 2/ 3 injection, which would not be suitable for patients experiencing side effects.
Poleg tega zdravljenja po uporabi injekcijske brizge s podaljšanim izločanjem ni mogoče zaustaviti, kar ne bi bilo primerno za bolnike, pri katerih se pojavijo neželeni učinki.
Therefore, the Committee decided that Zypadhera’ s benefits are greater than its risks for maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine.
Zaradi tega je odbor zaključil, da so koristi zdravila Zypadhera pri vzdrževalnemu zdravljenju odraslih s shizofrenijo, ki je dovolj stabilizirana med akutnim zdravljenju s peroralnim olazanpinom, večje od z njim povezanih tveganj.
The Committee recommended that Zypadhera be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Zypadhera odobri dovoljenje za promet.
Which measures are being taken to ensure the safe use of Zypadhera?
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Zypadhera?
The company that makes Zypadhera will provide an educational programme for doctors, nurses and pharmacists and a card for patients in all Member States, reminding them of how to use the medicine safely.
Družba, ki izdeluje zdravilo Zypadhera, bo pripravila izobraževalni program za zdravnike, sestre in farmacevte ter brošuro za bolnike v vseh državah članicah in jih opomnila o varni uporabi zdravila.
These will include information on what to do before and after each injection, the differences between Zypadhera and other injectable medicines containing olanzapine, and the recommendations on how patients should be monitored.
Pri tem bodo vključeni podatki o ukrepih pred vsakim vbrizganjem in po njem, razlikah med zdravilom Zypadhera ter drugimi zdravili, ki jih vbrizgamo in vsebujejo olanzapin, ter priporočila o spremljanju stanja bolnikov.
The European Commission granted a marketing authorisation valid throughout the EU for Zypadhera to Eli Lilly Nederland BV on 19 November 2008.
Druge informacije o zdravilu Zypadhera Evropska komisija je dovoljenje za promet z zdravilom Zypadhera, veljavno po vsej Evropski uniji, odobrila družbi Eli Lilly Nederland BV dne 19. novembra 2008.
The full EPAR for Zypadhera can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zypadhera je na voljo tukaj.
Route of EU number
velikost Številka EU
Pharmaceutical Form
farmacevtska oblika prašek in topilo za
powder and solvent for prolonged release suspension for injection
suspenzijo za injiciranje s
Intramuscular use
1 viala + 1 viala
Powder: vial (glass) Solvent: vial (glass)
podaljšanim sproščanjem prašek in topilo za
Powder:
Topilo: viala (steklena)
210 mg Solvent:
Topilo:
1 vial + 1 vial
prašek: viala (steklena)
300 mg Solvent:
Topilo:
Powder: vial (glass) Solvent: vial (glass)
podaljšanim sproščanjem
405 mg Solvent:
Topilo:
ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection.
ZYPADHERA 210 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem
Each vial contains olanzapine pamoate monohydrate equivalent to 210 mg olanzapine.
Ena viala vsebuje olanzapinijev pamoat monohidrat, ki ustreza 210 mg olanzapina.
After reconstitution each 1 ml suspension contains 150 mg olanzapine.
Po rekonstituciji 1 ml suspenzije vsebuje 150 mg olanzapina.
Powder and solvent for prolonged release suspension for injection:
Prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem:
Powder: yellow solid Solvent: clear, colourless to slightly yellow solution.
Prašek: trden rumen Vehikel: bistra, brezbarvna do rahlo rumena raztopina.
(See section 4.4)
(Glejte poglavje 4. 4.)
ZYPADHERA should only be administered by deep intramuscular gluteal injection by a healthcare professional trained in the appropriate injection technique and in locations where postinjection observation and access to appropriate medical care in the case of overdose can be assured.
Zdravilo ZYPADHERA lahko daje z uporabo globoke intramuskularne glutealne injekcije samo medicinsko osebje usposobljeno za ustrezno tehniko injiciranja na mestih, kjer je možno opazovanje po injiciranju in kjer je zagotovljen dostop za ustrezne medicinske ukrepe v primeru prevelikega odmerjanja.
After each injection, patients should be observed in a health care facility by appropriately qualified personnel for at least 3 hours for signs and symptoms consistent with olanzapine overdose.
Po vsakem injiciranju mora ustrezno usposobljeno osebje v zdravstvenih ustanovah najmanj 3 ure opazovati bolnike za znake in simptome značilne za preveliko odmerjanje olanzapina.
It should be confirmed that the patient is alert, oriented, and absent of any signs and symptoms of overdose.
Potrjeno mora biti, da je bolnik buden, orientiran in da nima znakov in simptomov prevelikega odmerjanja.
If an overdose is suspected, close medical supervision and monitoring should continue until examination indicates that signs and symptoms have resolved (See section 4.4.).
Če obstaja sum na preveliko odmerjanje, je potreben nadaljnji nadzor in spremljanje dokler preiskava ne potrdi, da so se znaki in simptomi izboljšali (glejte poglavje 4. 4).
For Instructions for Use, see section 6.6.
Za Navodila za uporabo, glejte poglavje 6. 6.
Do not confuse ZYPADHERA 210 mg powder and solvent for prolonged release suspension for injection with olanzapine 10 mg powder for solution for injection.
Ne zamenjajte zdravila ZYPADHERA 210 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem z olanzapin 10 mg praškom za raztopino za injiciranje.
2 Table 1
2 Tabela 1
Recommended dose scheme between oral olanzapine and ZYPADHERA
Priporočena shema odmerjanja med peroralnim olanzapinom in zdravilom ZYPADHERA
Target Oral Dose 10 mg/ day 15 mg/ day 20 mg/ day
10 mg/ dan 15 mg/ dan 20 mg/ dan
Olanzapine Recommended Starting Dose of Maintenance Dose after 2 Months of ZYPADHERA ZYPADHERA Treatment 210 mg/ 2 weeks or 405 mg/ 4 weeks 150 mg/ 2 weeks or 300 mg/ 4 weeks 300 mg/ 2 weeks 210 mg/ 2 weeks or 405 mg/ 4 weeks 300 mg/ 2 weeks 300 mg/ 2 weeks
150 mg/ 2 tedna ali 300 mg/ 4 tedne 210 mg/ 2 tedna ali 405 mg/ 4 tedne 300 mg/ 2 tedna
Dose Adjustment Patients should be monitored carefully for signs of relapse during the first one to two months of treatment.
Bolnike je v prvem enem do dveh mesecih zdravljenja potrebno skrbno spremljati za znake relapsa.